Ramesh Nathan is an Infectious Disease physician affiliated with Los Robles Hospital & Medical Center. OpenAlex indexes 41 publications with 370 citations (h-index 7).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
375 Rolling Oaks Dr Ste 210
Thousand Oaks, CA 913611028
Telephone
805-495-1073Provider last certified this registry record 18 Aug 2025.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Ferring Pharmaceuticals Inc.Program year20251 payment
- ABBVIE INC.Program year20253 payments
- Paratek Pharmaceuticals, Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
97.7%Lipopeptide Antibacterial95%Daptomycin100%Part D + Part B<11 patientsCephalosporin Antibacterial1.4%Ceftriaxone sodium93%Ceftriaxone5%Cefepime Hcl2%Part D + Part B<11 patients+ 16 more classes in this area
Cardiovascular
0.9%Statin0.4%Atorvastatin Calcium46%Rosuvastatin Calcium28%Simvastatin20%Pitavastatin Calcium7%Part D<11 patientsACE inhibitor0.2%Lisinopril76%Lisinopril-Hydrochlorothiazide24%Part D<11 patients+ 5 more classes in this area
Nervous system
0.5%SSRI0.2%Sertraline Hcl35%Escitalopram Oxalate29%Fluoxetine Hcl19%Trazodone Hcl17%Part D<11 patientsBenzodiazepine0.1%Alprazolam77%Temazepam23%Part D<11 patients+ 6 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Disseminated Aspergillosis After SARS-CoV-2 and BTK Inhibition: A Perfect Storm of Immunosuppression
Infectious Diseases in Clinical Practice
2025 - Silent Invader: A Case of Primary EBV Hepatitis in an Immunocompetent Adult
Private Practice Infectious Disease
2025 - Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization
Annals of Internal Medicine
2023
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”